Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Afatinib for Uterine Cancer
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing Afatinib, a drug used to treat other types of cancer, to see if it is effective in treating uterine serous carcinoma, a type of uterine cancer. The objectives are to see if the drug extends progression-free survival, overall survival, and has a good safety profile.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.